Durlobactam to boost the clinical utility of standard of care β-lactams against Mycobacterium abscessus lung disease
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.01046-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Dereje A Negatu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Anti-Bacterial Agents, Mycobacterium Infections, Nontuberculous, beta-Lactams. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, HHS | National Institutes of Health (NIH).
Abstract (Originalsprache)
β-Lactams present several desirable pharmacodynamic features leading to the rapid eradication of many bacterial pathogens. Imipenem (IPM) and cefoxitin (FOX) are injectable β-lactams recommended during the intensive treatment phase of pulmonary infections caused by Mycobacterium abscessus (Mab). However, their potency against Mab is many-fold lower than against Gram-positive and Gram-negative pathogens for which they were optimized, putting into question their clinical utility. Here, we show that adding the recently approved durlobactam-sulbactam (DUR-SUL) pair to either IPM or FOX achieves growth inhibition, bactericidal, and cytolytic activity at concentrations that are within those achieved in patients and below the clinical breakpoints established for each agent. Synergies between DUR-SUL and IPM or FOX were confirmed across a large panel of clinical isolates. Through in vitro resistant mutant selection, we also show that adding DUR-SUL abrogates acquired resistance to IPM and FOX. Since the use of β-lactam injectables is firmly grounded in clinical practice during the intensive treatment phase of Mab pulmonary disease, their potentiation by FDA-approved DUR-SUL to bring minimum inhibitory concentration distributions within achievable concentration ranges could offer significant short-term benefits to patients, while novel β-lactam combinations are optimized specifically against Mab pulmonary infections, for which no reliable cure exists.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
- Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa University, Addis Ababa, Ethiopia.
- Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
- Institute of Biotechnology, Addis Ababa University, Addis Ababa, Ethiopia.
- Department of Microbiology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seodaemun-gu, Seoul, South Korea.
- Institut für Medizinische Mikrobiologie, Universitat Zurich Institut fur Medizinische Mikrobiologie, Zürich, Switzerland.
ORCID-Profile: Sung Jae Shin, Peter Sander, Véronique Dartois, Thomas Dick
Förderung
- NIAID NIH HHS
- HHS | National Institutes of Health (NIH)
Zitieren
APA
Negatu, D. A., Aragaw, W. W., Gebresilase, T. T., Paruchuri, S., Kaya, F., Shin, S. J., Sander, P., Dartois, V., & Dick, T. (2025). Durlobactam to boost the clinical utility of standard of care β-lactams against Mycobacterium abscessus lung disease. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01046-24
Vancouver
Negatu DA, Aragaw WW, Gebresilase TT, Paruchuri S, Kaya F, Shin SJ, et al. Durlobactam to boost the clinical utility of standard of care β-lactams against Mycobacterium abscessus lung disease. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01046-24
BibTeX
@article{Negatu2025,
author = {Negatu, Dereje A and Aragaw, Wassihun Wedajo and Gebresilase, Tewodros T and Paruchuri, Sindhuja and Kaya, Firat and Shin, Sung Jae and Sander, Peter and Dartois, Véronique and Dick, Thomas},
title = {Durlobactam to boost the clinical utility of standard of care β-lactams against Mycobacterium abscessus lung disease},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.01046-24}
}
EUVIMED